PMV Pharma Stock (NASDAQ:PMVP), Trade Ideas

PMV Pharma

PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

BLPH

BPTH

BSFC

BYSI

CELU

CISS

CMTL

CTHR

EDSA

GRPN

HRMY

LGMK

LIFW

NUWE

OBLG

OTLK

PCSA

PMVP

PSQH

RBBN

RDHL

RERE

RSLS

SASI

SAVA

SECO

SNCR

SOPA

STAF

STKL

STRL

TIRX

TNGX

VSAT

Gainers


	Sigma Additive Solutions, Inc.  (NASDAQ: SASI) shares jumped 196% to $7.34 after the company announced the signing of a definitive agreement for the acquisition of NextTrip Holdings, Inc.


Why Belden Shares Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Biotech

Health Care

General

PMV Pharmaceuticals Inc (NASDAQ: PMVP) announced updated Phase 1 results from its ongoing Phase 1/2 PYNNACLE trial that showed PC14586 achieved efficacy in heavily pretreated patients across multiple tumor types and was well tolerated with a 

Precision Oncology PMV Pharmaceuticals Reveals Early Data From Cancer Study In Pretreated Patients

AMTI

AONC

ATEX

AVTX

CETX

CLDI

CONNEXA SPORTS TECH INC by Connexa Sports Technologies Inc.

CNXA

CPTN

ELUT

FEAM

FFIE

FISK

FLUX

GLBS

HSCS

ICPT

MDBH

MKUL

MLGO

MOND

MORF

MURF

NEPT

NXPL

PBTS

PHAR

SCHL

SNPX

STTK

SWIN

TIGR

UPTD

VNRX

Gainers

MicroAlgo Inc.  (NASDAQ: MLGO) shares jumped 74% to $7.02 after it unveiled a knowledge-enhanced backtracking search algorithm to boost the performance and efficiency of research institutions.

Why Flux Power Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

PMV Pharmaceuticals Inc

Mizuho analyst Uy Ear maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Neutral and lowers the price target from $20 to $18.

Price Target

Analyst Ratings

SAGE

Mizuho Maintains Neutral on Sage Therapeutics, Lowers Price Target to $18

JP Morgan analyst Bill Peterson maintains Enovix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) with a Overweight and lowers the price target from $18 to $12.

ENVX

JP Morgan Maintains Overweight on Enovix, Lowers Price Target to $12

Wedbush analyst Matt Bryson maintains Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) with a Neutral and lowers the price target from $40 to $32.5.

INTC

Wedbush Maintains Neutral on Intel, Lowers Price Target to $32.5

JP Morgan analyst Doug Anmuth maintains Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) with a Overweight and raises the price target from $165 to $200.

GOOGL

JP Morgan Maintains Overweight on Alphabet, Raises Price Target to $200

Mizuho analyst Ben Chaiken maintains Royal Caribbean Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) with a Buy and raises the price target from $164 to $168.

Mizuho Maintains Buy on Royal Caribbean Gr, Raises Price Target to $168

Wedbush analyst Michael Pachter maintains Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) with a Outperform and lowers the price target from $80 to $75.

ROKU

Wedbush Maintains Outperform on Roku, Lowers Price Target to $75

Alejandro Cao de Benós, the primary Western contact for business with Kim Jong Un&#8217;s North Korea, is facing scrutiny from U.S. authorities for alleged violations of sanctions.
What Happened: Cao de Benós, a resident of Tarragona, Spain, and an IT consultant is a semi-official spokesperson for North Korea. He previously organized North Korea&#8217;s first cryptocurrency conference, which, according to U.S. authorities, violated sanctions. The FBI sought his extradition, leading to his arrest by Spanish police in late 2023. He was later released pending extradition.
In an interview with <a href="https://www.bloomberg.com/news/articles/2024-04-25/how-alejandro-cao-de-benos-north-korea-s-man-in-spain-ran-afoul-of-the-us?srnd=homepage-asia">Bloomberg</a>, Cao de Benós revealed that despite the charges, he is &#8220;not going to stop&#8221; his activities and is &#8220;not afraid.&#8221;
Cao de Benós is accused of violating the International Emergency Economic Powers Act, a U.S. law often used to target alleged violators of sanctions against North Korea. 
His passport is currently in Spanish custody due to an unrelated firearms charge. Cao de Benós claims that the U.S. has withdrawn its extradition request. He provided Bloomberg with purported email exchanges between the U.S. Embassy and the Spanish Ministry of Foreign Affairs, suggesting a lack of &#8220;dual criminality&#8221; between the two countries regarding the charges.
"I'm just a person up against the biggest empire of this time, the US, which has a lot of resources, with millions [of dollars] dedicated to destroying North Korea,&#8221; Cao de Benós said.
Despite the ongoing legal issues, Cao de Benós considers this a victory, stating, &#8220;Having won this first battle against the U.S., it shows me that I&#8217;m going in the right direction.&#8221;
See Also: <a href="https://www.benzinga.com/news/24/04/38405064/anthony-scaramucci-says-nikki-haley-is-still-polling-nicely-in-pa-despite-ending-bid-against-trump-a?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Anthony Scaramucci Says Nikki Haley Is Still Polling &#8216;Nicely&#8217; In PA, Despite Ending Bid Against Trump: &#8216;A</a>
Why It Matters: This case follows a pattern of North Korea&#8217;s alleged use of cryptocurrency to evade sanctions. In 2022, <a href="https://www.benzinga.com/markets/cryptocurrency/22/04/26804761/former-ethereum-developer-and-two-european-citizens-charged-for-conspiring-over-north-kore">Cao de Benós and a U.K. businessman </a>were accused of recruiting an Ethereum developer to help North Korea evade U.S. sanctions. 
Furthermore, a UN Security Council investigation revealed that North Korea obtains <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37896655/un-says-north-korea-steals-billions-in-crypto-to-fund-doomsday-weapons">about half of its foreign currency earnings</a> from cyberattacks on cryptocurrency-related firms, causing an estimated $3 billion in damages. 
Read Next: <a href="https://www.benzinga.com/news/24/04/38395938/kim-jong-uns-sister-pledges-to-build-north-koreas-overwhelming-military-power-amid-rising-regional-t?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Kim Jong Un&#8217;s Sister Pledges To Build North Korea&#8217;s &#8216;Overwhelming&#8217; Military Power Amid Rising Regional Tensions</a>
Image via Shutterstock
<div style="font-family: 'Lato', sans-serif">
<div>
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by Benzinga Neuro, Edited by 
 <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Pooja Rajkumari</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>
</div>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Politics

Kim Jong Un's Liaison Faces Heat From US For Violating Sanctions, Says He Is 'Not Afraid:' 'I'm Just A Person Up Against The Biggest Empire Of This Time'

Mizuho analyst Nitin Kumar reiterates Range Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>) with a Buy and raises the price target from $39 to $41.

Reiteration

Mizuho Reiterates Buy on Range Resources, Raises Price Target to $41

Private psychedelics medicine company&nbsp;Beckley Psytech Ltd&nbsp;announced this week that the&nbsp;first patient has been dosed&nbsp;in the second part of its two-part Phase IIa&nbsp;<a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT05660642" rel="noreferrer noopener">study</a>&nbsp;evaluating BPL-003 in patients with treatment-resistant depression (TRD). BPL-003 is its proprietary intranasal formulation of synthetic 5-MeO-DMT for treatment-resistant depression (TRD.)
&#8220;Understanding the safety, tolerability and efficacy of BPL-003 in people who are taking SSRIs is a critical step in our journey to bringing BPL-003 to market as a safe, effective&nbsp;and&nbsp;convenient treatment opportunity for both patients and providers," stated Dr.&nbsp;Rob Conley,&nbsp;chief scientific and medical officer at Beckley Psytech. "We are looking forward to better understanding BPL-003 as an adjunctive therapy ahead of end-of-Phase II interactions with regulatory authorities, and we are thankful to the patients and study partners who have helped us reach this important milestone in our clinical development of BPL-003. "
See Also:&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/cannabis/24/01/36494530/atai-invests-50m-in-beckley-psytech-for-short-duration-psychedelics-development" rel="noreferrer noopener">Atai Invests $50M In Beckley Psytech For Short-Duration Psychedelics Development</a>
<h2 class="wp-block-heading">Study Highlights</h2>
Treatment-resistant depression affects around 30% of people with major depressive disorder, or depression, and is diagnosed when an individual does not respond to two or more antidepressants. Many studies exploring potential new medications for TRD require patients to taper off their existing treatments. However, since TRD is often managed with the use of several interventions, it is important to understand how different treatment options interact, which is why Beckley Psytech is exploring the safety and efficacy of BPL-003 co-administration with Selective Serotonin Reuptake Inhibitors (SSRIs) in this study.
In this part of the study patients with moderate-to-severe TRD who are also taking certain defined SSRIs will receive a single dose of BPL-003 alongside psychological support to explore the safety, tolerability, efficacy and pharmacokinetics of BPL-003 as an adjunctive therapy to SSRIs. 
Patients will be followed for 12 weeks post-dosing with assessments conducted at multiple points throughout the period. 
Initial results from this part of the study are expected to be shared in the first half of 2025. 
Part 1 of the study&nbsp;was in patients who were not taking antidepressants with initial results showing that a single dose of BPL-003 was safe and well-tolerated, with a rapid and durable antidepressant effect lasting up to 85 days post-dose.
A Phase IIb trial of BPL-003 is also currently underway, evaluating the effects of a single medium or high dose of BPL-003 against a sub-perceptual dose in TRD patients who are not taking concomitant antidepressants. Initial results from that study are expected in the second half of the year.&nbsp;
Photo: Courtesy of agsandrew via Shutterstock

Cannabis

Psychedelics

First Patient Dosed In Psychedelics Therapy Study  For Treatment-Resistant Depression

Domino&#8217;s Pizza, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) is scheduled to post earnings results for its first quarter, before the <a href="https://www.benzinga.com/quote/DPZ/earnings">opening bell on April 29, 2024</a>.
Analysts expect the Ann Arbor, Michigan-based company to report quarterly earnings at $3.39 per share, up from $2.93 per share in the year-ago period. Domino&#8217;s is projected to report quarterly revenue of $1.08 billion, up from $1.02 billion in the year-earlier quarter, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On April 16, UBS analyst Dennis Geiger maintained Domino&#8217;s Pizza with a Buy and raised the price target from $526 to $570, while Jefferies analyst Andy Barish maintained the stock with a Hold and increased the price target from $455 to $480.
With the recent buzz around Domino&#8217;s Pizza, some investors may be eyeing potential gains from the company's dividends. As of now, Domino&#8217;s Pizza has a dividend yield of 1.22%, which is a quarterly dividend amount of $1.51 a share ($6.04 a year).
To figure out how to earn $500 monthly from Domino&#8217;s, we start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by Domino&#8217;s $6.04 dividend: $6,000 / $6.04 &nbsp;= 993 shares
So, an investor would need to own approximately $491,307 worth of Domino&#8217;s, or 993 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $6.04 = 199 shares, or $98,459 to generate a monthly dividend income of $100.
Also Read: <a href="https://www.benzinga.com/news/24/04/38430578/top-3-financial-stocks-that-could-sink-your-portfolio-this-quarter">Top 3 Financial Stocks That Could Sink Your Portfolio This Quarter</a>
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
DPZ Price Action: Shares of Domino&#8217;s rose 1.5% to close at $494.77 on Thursday.
Read More: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38430580/glucotrack-and-2-other-stocks-under-1-insiders-are-buying">GlucoTrack And 2 Other Stocks Under $1 Insiders Are Buying</a>
Image: Courtesy of Domino&#8217;s

Earnings

Long Ideas

Dividends

How To Earn $500 A Month From Domino's Pizza Stock Ahead Of Q1 Earnings

Jefferies analyst Brent Thill maintains Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) with a Buy and raises the price target from $180 to $200.

Jefferies Maintains Buy on Alphabet, Raises Price Target to $200

Mizuho analyst John Roberts maintains Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) with a Neutral and raises the price target from $91 to $102.

Mizuho Maintains Neutral on Eastman Chemical, Raises Price Target to $102

Wedbush analyst Daniel Ives reiterates Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) with a Outperform and maintains $500 price target.

MSFT

Wedbush Reiterates Outperform on Microsoft, Maintains $500 Price Target

Tompkins Financial Corporation announced today that its Board of Directors approved payment of a regular quarterly cash dividend of $0.61 per share, payable on May 17, 2024, to common shareholders of record on May 10, 2024. The dividend amount represents an increase of $0.01 per share, or 1.6% over the dividend paid in the second quarter of 2023.

Tompkins Financial Increases Quarterly Cash Dividend From $0.60 To $0.61 Per Share

Mizuho analyst Nitin Kumar maintains EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) with a Neutral and raises the price target from $40 to $43.

Mizuho Maintains Neutral on EQT, Raises Price Target to $43

Compass Point analyst Giuliano Bologna maintains FTAI Aviation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>) with a Buy and raises the price target from $71 to $88.

FTAI

Compass Point Maintains Buy on FTAI Aviation, Raises Price Target to $88

Wedbush's Dan Ives heaped praise on Google&#8216;s parent Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) after the company beat revenue and earnings per share (EPS) estimates in its <a href="https://www.benzinga.com/news/earnings/24/04/38445001/alphabet-q1-earnings-revenue-beat-eps-beat-70b-buyback-first-ever-dividend-ai-leadership-and-more">March 2024 quarter results</a>.
What Happened: Ives expressed his admiration for Google following the company&#8217;s Q1 earnings, where it declared its first-ever dividend.
In an interview with CNBC, Ives described the results as &#8220;a quarter they should frame and put in the Louvre,&#8221; adding that he sees nothing negative in the report.
He also highlighted the positive implications for near-term growth and margin, as well as the management&#8217;s comments on search generative experience (SGE,) which should ease long-term investor concerns.
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38453639/another-picasso-like-performance-top-tech-analyst-praises-satya-nadella-says-micros">&#8216;Another Picasso-Like Performance:&#8217; Top Tech Analyst Praises Satya Nadella, Says Microsoft Is Top &#8216;AI Draft Pick&#8217; With 20% Rally In Store</a>
He concluded by noting that the AI and cloud story is now unfolding and increased the price target for Google to $205 from $175.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&quot;This is a quarter they should frame and put in the Louvre&quot; &#8211; <a href="https://twitter.com/Wedbush?ref_src=twsrc%5Etfw">@Wedbush</a> <a href="https://twitter.com/DivesTech?ref_src=twsrc%5Etfw">@DivesTech</a> on Alphabet. &quot;There is nothing in here that I view as a negative&quot;<a href="https://twitter.com/search?q=%24GOOGL&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$GOOGL</a> <a href="https://twitter.com/jonfortt?ref_src=twsrc%5Etfw">@JonFortt</a> <a href="https://t.co/z7zv4HhRRT">pic.twitter.com/z7zv4HhRRT</a>
&mdash; CNBCOvertime (@CNBCOvertime) <a href="https://twitter.com/CNBCOvertime/status/1783596481246564418?ref_src=twsrc%5Etfw">April 25, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: Alphabet reported a 15% year-over-year revenue increase to $80.539 billion, beating the consensus estimate of $78.594 billion. The company also reported quarterly EPS of $1.89, surpassing analyst estimates of $1.51.
During the company&#8217;s first-quarter earnings call, CEO Sundar Pichai expressed satisfaction with the development of the company&#8217;s <a href="https://www.benzinga.com/news/24/04/38450195/alphabet-ceo-sundar-pichai-lauds-progress-despite-controversies-surrounding-google-gemini-developer">Gemini AI</a>, despite <a href="https://www.benzinga.com/news/24/02/37258050/elon-musk-pushes-xais-grok-ai-chatbot-after-google-gemini-comes-under-fire-truth-never-been-more-ess">recent controversies</a>. He highlighted the significant advancements made in the development of the Gemini AI and other models.
Pichai also addressed the changes in user behavior and the potential impact on the <a href="https://www.benzinga.com/news/24/04/38450393/alphabet-ceo-very-very-confident-that-it-wont-be-costly-to-serve-search-experience-with-generative-a">new Search experience</a> given the integration of generative answers during the first-quarter earnings call, expressing confidence in the company&#8217;s ability to manage these challenges.
Deepwater Asset Management's <a href="https://www.benzinga.com/news/earnings/24/04/38450406/gene-munster-applauds-sundar-pichais-100b-revenue-projection-for-google-parent-alphabet-a-sign-of-e">Gene Munster applauded</a> Google's $100 billion revenue projection, saying it's a sign that the company is "entering a new growth phase."
Price Action:&nbsp;Alphabet Inc.'s shares were up 11.80% in premarket trading on Friday, after closing at $157.95 on the previous day, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:&nbsp;<a href="https://www.benzinga.com/news/24/04/38426370/mark-zuckerberg-says-tens-of-millions-users-have-already-tried-meta-ai-and-people-are-asking-us-to-r" target="_blank" rel="noreferrer noopener">Mark Zuckerberg Says ‘Tens Of Millions' Users Have Already Tried Meta AI, And People Are ‘Asking Us To Release…Wherever They Are'</a>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Photo courtesy: World Economic Forum on Flickr

Analyst Color

Equities

Tech

GOOG

'Put It In The Louvre:' Tech Bull Praises Google Parent Alphabet's 'Major Breakout Quarter,' Says It Is 'Now In The Party'

Asset Sales

Safe And Green Development Executes Contract To Sell Lago Vista Site; Closing Of Transaction Would Result In ~$5

Enables Customers to Optimize Carbon Capture Value Chain Investments
Co-development with Aramco Spurs Launch of Expanded Co-Innovation Program to Deliver Solutions Across Multiple Sustainability Pathways
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.aspentech.com%2F&amp;esheet=53957164&amp;newsitemid=20240426875777&amp;lan=en-US&amp;anchor=Aspen+Technology%2C+Inc.&amp;index=1&amp;md5=17e2dd7d2b854c0a5f244bc36287cd21">Aspen Technology, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZPN#NASDAQ">AZPN</a>), a global leader in industrial software, today introduced AspenTech Strategic Planning for Sustainability Pathways&#x2122; – a new and unique integrated modelling and optimization solution that aims to guide companies in carbon capture utilization and storage decision making and sustainability strategy investments. The AspenTech Strategic Planning solution was developed through a <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.aspentech.com%2Fen%2Fresources%2Fpress-releases%2Faspentech-and-saudi-aramco-partner&amp;esheet=53957164&amp;newsitemid=20240426875777&amp;lan=en-US&amp;anchor=licensing+agreement&amp;index=2&amp;md5=898c19b0ad2926a5a3f95729175736ba">licensing agreement</a> with Aramco, one of the world's leading integrated energy and chemicals companies. Based on this successful effort, AspenTech also announced that it is launching an expanded co-innovation program to bring together leading owner operators and EPC companies to collaboratively innovate a wider strategic planning solution portfolio to attempt to optimize across multiple sustainability pathways.
As companies make significant investments in technologies to mitigate greenhouse gas emissions, AspenTech's Strategic Planning solution aims for these large capital investments to drive value and impact sustainability goals. They are also expected to support long-term operational performance objectives.
Rasha Hasaneen, Chief Product and Sustainability Officer at Aspen Technology said, "Asset intensive industries play a critical role in the path to global net-zero, and carbon capture is an important pathway for our customers and requires significant capital investment. This is the focus of our new strategic planning solution – helping to optimize CAPEX and OPEX investments across the entire carbon capture value chain."
Dr. Vikas Dhole, General Manager, Sustainability Solutions at Aspen Technology, said "Carbon capture is but one sustainability pathway. Through the expanded co-innovation program, we will continue to broaden our solutions into other pathways to help the asset intensive industries to simultaneously address sustainability and operational performance objectives, given the significant investment that is projected in this area."
To learn more about AspenTech's solutions and its co-innovation program, please visit <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.aspentech.com%2Fen%2Finsights%2Fsustainability&amp;esheet=53957164&amp;newsitemid=20240426875777&amp;lan=en-US&amp;anchor=AspenTech+Sustainability&amp;index=3&amp;md5=72c5d731462dfd0202e1a8c05d5735cf">AspenTech Sustainability</a>.

AZPN

Aspen Technology Introduces New Strategic Planning For Sustainability Pathways Solution; Enables Customers To Optimize Carbon Capture Value Chain Investments; Co-Development With Aramco Spurs Launch Of Expanded Co-Innovation Program To Deliver Solutions Across Multiple Sustainability Pathways

WIIM

XPO shares are trading lower in possible sympathy with Saia, which reported worse-than-expected Q1 financial results.

PMV Pharmaceuticals Inc (PMVP) stock is down -78.63% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver's proprietary ranking system, gives PMVP stock a score of  32 out of a possible 100. That rank is  influenced by a short-term technical score of 2. PMVP's rank al

PMV Pharmaceuticals Inc (PMVP) Stock  Falls -15.69% This Week: Is It a Good Pick?

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on PMV Pharmaceuticals (PMVP – Research Report). The company's share...

TD Cowen Reaffirms Their Buy Rating on PMV Pharmaceuticals (PMVP)

Oppenheimer analyst Jeff Jones maintained a Hold rating on PMV Pharmaceuticals (PMVP – Research Report) today. The company's shares closed yesterda...

Oppenheimer Keeps Their Hold Rating on PMV Pharmaceuticals (PMVP)

PMV Pharmaceuticals reports FY results

Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on PMV Pharmaceuticals (PMVP – Research Report). The associated price targ...

PMV Pharmaceuticals: Buy Rating Affirmed Amid Strong Financials and Promising Clinical Prospects

Big Pharma patent cliffs seen fueling oncology M&A this year

Cantor Fitzgerald sees strong year ahead for oncology M&A

Cantor sees strong year ahead for oncology M&A

Oppenheimer Remains a Hold on PMV Pharmaceuticals (PMVP)

The 46 rating InvestorsObserver gives to PMV Pharmaceuticals Inc (PMVP)  stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 40 percent of stocks in the Biotechnology industry, PMVPâ€&#x2122;s 46 overall rating means the stock scores better than 46 percent of all stocks. PMVP has an Overa

Should Biotechnology Stock PMV Pharmaceuticals Inc (PMVP) Be in Your Portfolio Wednesday?

ALXO

AMAM

ARVN

BCYC

CGON

DAWN

DCPH

ERAS

EXEL

FUSN

GERN

HARP

IDYA

IMCR

IMTX

JANX

KPTI

KURA

LEGN

MRUS

NUVL

OLMA

ORIC

RLAY

RVMD

SNDX

SWTX

URGN

VSTM

ZNTL

Press Releases

PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar

PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation

PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights